”I think it was a very ambitious goal, and I think we are well on track to get to that goal.”
As President and CEO of Genmab, Jan van de Winkel creates purpose by setting ambitious goals. He delivered a compelling session at Aarhus Symposium 2018 presenting insights into how Genmab works towards creating the future of cancer treatment.
Since Genmabs foundation in 1999, their success is often accredited to their world-class research and development efforts and successful strategic alliances with top-tier pharmaceutical and bio-tech companies. As a result, Genmab was included in Forbes’ list of the world’s most innovative companies in 2017.
Watch the interview or experience the full session here to find out why setting ambitious goals is important for both Jan van de Winkel and Genmab.